Delphine BADINAND
MD
-
Onco-radiotherapist at the Timone Hospital
APHM
MI is a diamond of the new Metropolis, offering a unique opportunity to drive science forward and provide more effective therapeutic options for our cancer patients.
Cancerology is booming and immunotherapy represents the most promising approach. At the APHM we have been at the forefront of these therapeutic advances and as a radiotherapist, I’m developing new strategies combining radiotherapy and immunotherapy to reach the « abscopal effect ». MI is a diamond of the new Metropolis, offering a unique opportunity to drive science forward and provide more effective therapeutic options for our cancer patients.
#cliniqueHave a look on our testimonies
“Our immunotherapy antibodies are positioned at the crossroads of two immunology fields with high potential: the γ9δ2 T cells and a novel superfamily of immunomodulators, butyrophilins”
Pierre d’EPENOUX
Imcheck Therapeutics
“Projects like PIONeeR allow us to contribute to the understanding of resistance to immunotherapy while opening clinical research to patients in Corsica, who, until recently, had no choice other than to fly to Marseille or Paris for such opportunities.”
Stéphane PROVENT
Centre Hospitalier, Clinique Maymard, Bastia
Thanks to this unprecedented alliance of researchers, clinicians, technological platforms and industrials we should be able to quickly do much better
Vincent BARLOGIS
AP-HM
The Explore covid-19 project was born from combining the forces of Marseille Immunopôle. It should lead us to better understand this new disease and improve the prognosis of our patients.
Julien CARVELLI
AP-HM
your commitment to MI